1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Duchenne Muscular Dystrophy Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Duchenne Muscular Dystrophy Therapeutics Market, by Therapy Type
8.1.1. Exon Skipping Therapies
8.1.1.1. Market Revenue and Forecast
8.1.2. Gene Therapy
8.1.2.1. Market Revenue and Forecast
8.1.3. Corticosteroids
8.1.3.1. Market Revenue and Forecast
8.1.4. Stop Codon Read-through Therapies
8.1.4.1. Market Revenue and Forecast
8.1.5. Cell-based Therapies
8.1.5.1. Market Revenue and Forecast
8.1.6. Combination Therapies
8.1.6.1. Market Revenue and Forecast
8.1.7. Supportive Care Therapies
8.1.7.1. Market Revenue and Forecast
9.1. Duchenne Muscular Dystrophy Therapeutics Market, by Disease Stage
9.1.1. Early-stage DMD
9.1.1.1. Market Revenue and Forecast
9.1.2. Ambulatory DMD
9.1.2.1. Market Revenue and Forecast
9.1.3. Non-ambulatory DMD
9.1.3.1. Market Revenue and Forecast
9.1.4. Advanced-stage DMD
9.1.4.1. Market Revenue and Forecast
10.1. Duchenne Muscular Dystrophy Therapeutics Market, by Route of Administration
10.1.1. Intravenous (IV)
10.1.1.1. Market Revenue and Forecast
10.1.2. Oral
10.1.2.1. Market Revenue and Forecast
10.1.3. Intramuscular
10.1.3.1. Market Revenue and Forecast
10.1.4. Subcutaneous
10.1.4.1. Market Revenue and Forecast
11.1. Duchenne Muscular Dystrophy Therapeutics Market, by End-User
11.1.1. Hospitals
11.1.1.1. Market Revenue and Forecast
11.1.2. Specialty Neuromuscular Clinics
11.1.2.1. Market Revenue and Forecast
11.1.3. Homecare Settings
11.1.3.1. Market Revenue and Forecast
11.1.4. Rehabilitation Centers
11.1.4.1. Market Revenue and Forecast
11.1.5. Research and Academic Institutes
11.1.5.1. Market Revenue and Forecast
12.1. Duchenne Muscular Dystrophy Therapeutics Market, by Distribution Channel
12.1.1. Hospital Pharmacies
12.1.1.1. Market Revenue and Forecast
12.1.2. Specialty Pharmacies
12.1.2.1. Market Revenue and Forecast
12.1.3. Online Pharmacies
12.1.3.1. Market Revenue and Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Therapy Type
13.1.2. Market Revenue and Forecast, by Disease Stage
13.1.3. Market Revenue and Forecast, by Route of Administration
13.1.4. Market Revenue and Forecast, by End-User
13.1.5. Market Revenue and Forecast, by Distribution Channel
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Therapy Type
13.1.6.2. Market Revenue and Forecast, by Disease Stage
13.1.6.3. Market Revenue and Forecast, by Route of Administration
13.1.6.4. Market Revenue and Forecast, by End-User
13.1.6.5. Market Revenue and Forecast, by Distribution Channel
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Therapy Type
13.1.7.2. Market Revenue and Forecast, by Disease Stage
13.1.7.3. Market Revenue and Forecast, by Route of Administration
13.1.7.4. Market Revenue and Forecast, by End-User
13.1.7.5. Market Revenue and Forecast, by Distribution Channel
13.2. Europe
13.2.1. Market Revenue and Forecast, by Therapy Type
13.2.2. Market Revenue and Forecast, by Disease Stage
13.2.3. Market Revenue and Forecast, by Route of Administration
13.2.4. Market Revenue and Forecast, by End-User
13.2.5. Market Revenue and Forecast, by Distribution Channel
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Therapy Type
13.2.6.2. Market Revenue and Forecast, by Disease Stage
13.2.6.3. Market Revenue and Forecast, by Route of Administration
13.2.7. Market Revenue and Forecast, by End-User
13.2.8. Market Revenue and Forecast, by Distribution Channel
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Therapy Type
13.2.9.2. Market Revenue and Forecast, by Disease Stage
13.2.9.3. Market Revenue and Forecast, by Route of Administration
13.2.10. Market Revenue and Forecast, by End-User
13.2.11. Market Revenue and Forecast, by Distribution Channel
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Therapy Type
13.2.12.2. Market Revenue and Forecast, by Disease Stage
13.2.12.3. Market Revenue and Forecast, by Route of Administration
13.2.12.4. Market Revenue and Forecast, by End-User
13.2.13. Market Revenue and Forecast, by Distribution Channel
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Therapy Type
13.2.14.2. Market Revenue and Forecast, by Disease Stage
13.2.14.3. Market Revenue and Forecast, by Route of Administration
13.2.14.4. Market Revenue and Forecast, by End-User
13.2.15. Market Revenue and Forecast, by Distribution Channel
13.3. APAC
13.3.1. Market Revenue and Forecast, by Therapy Type
13.3.2. Market Revenue and Forecast, by Disease Stage
13.3.3. Market Revenue and Forecast, by Route of Administration
13.3.4. Market Revenue and Forecast, by End-User
13.3.5. Market Revenue and Forecast, by Distribution Channel
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Therapy Type
13.3.6.2. Market Revenue and Forecast, by Disease Stage
13.3.6.3. Market Revenue and Forecast, by Route of Administration
13.3.6.4. Market Revenue and Forecast, by End-User
13.3.7. Market Revenue and Forecast, by Distribution Channel
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Therapy Type
13.3.8.2. Market Revenue and Forecast, by Disease Stage
13.3.8.3. Market Revenue and Forecast, by Route of Administration
13.3.8.4. Market Revenue and Forecast, by End-User
13.3.9. Market Revenue and Forecast, by Distribution Channel
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Therapy Type
13.3.10.2. Market Revenue and Forecast, by Disease Stage
13.3.10.3. Market Revenue and Forecast, by Route of Administration
13.3.10.4. Market Revenue and Forecast, by End-User
13.3.10.5. Market Revenue and Forecast, by Distribution Channel
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Therapy Type
13.3.11.2. Market Revenue and Forecast, by Disease Stage
13.3.11.3. Market Revenue and Forecast, by Route of Administration
13.3.11.4. Market Revenue and Forecast, by End-User
13.3.11.5. Market Revenue and Forecast, by Distribution Channel
13.4. MEA
13.4.1. Market Revenue and Forecast, by Therapy Type
13.4.2. Market Revenue and Forecast, by Disease Stage
13.4.3. Market Revenue and Forecast, by Route of Administration
13.4.4. Market Revenue and Forecast, by End-User
13.4.5. Market Revenue and Forecast, by Distribution Channel
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Therapy Type
13.4.6.2. Market Revenue and Forecast, by Disease Stage
13.4.6.3. Market Revenue and Forecast, by Route of Administration
13.4.6.4. Market Revenue and Forecast, by End-User
13.4.7. Market Revenue and Forecast, by Distribution Channel
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Therapy Type
13.4.8.2. Market Revenue and Forecast, by Disease Stage
13.4.8.3. Market Revenue and Forecast, by Route of Administration
13.4.8.4. Market Revenue and Forecast, by End-User
13.4.9. Market Revenue and Forecast, by Distribution Channel
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Therapy Type
13.4.10.2. Market Revenue and Forecast, by Disease Stage
13.4.10.3. Market Revenue and Forecast, by Route of Administration
13.4.10.4. Market Revenue and Forecast, by End-User
13.4.10.5. Market Revenue and Forecast, by Distribution Channel
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Therapy Type
13.4.11.2. Market Revenue and Forecast, by Disease Stage
13.4.11.3. Market Revenue and Forecast, by Route of Administration
13.4.11.4. Market Revenue and Forecast, by End-User
13.4.11.5. Market Revenue and Forecast, by Distribution Channel
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Therapy Type
13.5.2. Market Revenue and Forecast, by Disease Stage
13.5.3. Market Revenue and Forecast, by Route of Administration
13.5.4. Market Revenue and Forecast, by End-User
13.5.5. Market Revenue and Forecast, by Distribution Channel
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Therapy Type
13.5.6.2. Market Revenue and Forecast, by Disease Stage
13.5.6.3. Market Revenue and Forecast, by Route of Administration
13.5.6.4. Market Revenue and Forecast, by End-User
13.5.7. Market Revenue and Forecast, by Distribution Channel
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Therapy Type
13.5.8.2. Market Revenue and Forecast, by Disease Stage
13.5.8.3. Market Revenue and Forecast, by Route of Administration
13.5.8.4. Market Revenue and Forecast, by End-User
13.5.8.5. Market Revenue and Forecast, by Distribution Channel
14.1. Sarepta Therapeutics
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Pfizer Inc.
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Roche Holding AG
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. PTC Therapeutics
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Solid Biosciences Inc.
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Catalyst Pharmaceuticals
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Santhera Pharmaceuticals
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Wave Life Sciences
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Dyne Therapeutics
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Avidity Biosciences
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
